Sanofi’s multiple sclerosis candidate tolebrutinib is in line for a potential US approval in the autumn after the Food and Drug Administration agreed to a speedy review of the oral Bruton’s tyrosine kinase (BTK) inhibitor.
The regulatory agency is evaluating tolebrutinib under priority review for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS) and...